The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965 · cited 1×
“Corticotropin-releasing factor (CRF) has been identified as a neuropeptide that plays a central role in the coordination of neuroendocrine, autonomic, and behavioral responses to stress (Vale et al., 1981).”
Background
Cited by
Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605
Bourin, M., & Hascoët, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01274-3 · Cited by 1,427
CRF and CRF receptors: role in stress responsivity and other behaviors
Bale, T. L., & Vale, W. W. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121410 · Cited by 1,270
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Neuroendocrine pharmacology of stress
Carrasco, G. A., & Van de Kar, L. D. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01285-8 · Cited by 914
Cryan, J. F., & Mombereau, C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001457 · Cited by 616
The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Surget, A., Saxe, M., Leman, S., Ibarguen-Vargas, Y., Chalon, S., Griebel, G., Hen, R., & Belzung, C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.022 · Cited by 556
Self-citationA key role for corticotropin-releasing factor in alcohol dependence
Heilig, M., & Koob, G. F. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.006 · Cited by 503
A trans-dimensional approach to the behavioral aspects of depression
Bessa, J. M. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.001.2009 · Cited by 469
The Flinders Sensitive Line rat: A selectively bred putative animal model of depression
Overstreet, D. H., Friedman, E., Mathé, A. A., & Yadid, G. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.015 · Cited by 380
Hauger, R., Risbrough, V., Brauns, O., & Dautzenberg, F. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706777950684 · Cited by 343
Alonso, R., Griebel, G., Pavone, G., Stemmelin, J., Le Fur, G., & Soubrié, P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001464 · Cited by 319
Self-citationSommer, W. H., Rimondini, R., Hansson, A. C., Hipskind, P. A., Gehlert, D. R., Barr, C. S., & Heilig, M. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.010 · Cited by 309
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295
Self-citationCellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder
Zarate, C. A., Singh, J., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.021 · Cited by 274
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
Roozendaal, B., Brunson, K. L., Holloway, B. L., McGaugh, J. L., & Baram, T. Z. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212504599 · Cited by 259
Role of kappa-opioid receptors in stress and anxiety-related behavior
Van’t Veer, A., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 257
Adriaan Bouwknecht, J., Olivier, B., & Paylor, R. E. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.02.002 · Cited by 256
Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253
Self-citationRole of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression
Hauger, R. L., Risbrough, V., Oakley, R. H., Olivares‐Reyes, J. A., & Dautzenberg, F. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05011.x · Cited by 217
Bosch, O. J., Nair, H. P., Ahern, T. H., Neumann, I. D., & Young, L. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.154 · Cited by 216
Sahuque, L. L., Kullberg, E. F., Mcgeehan, A. J., Kinder, J. R., Hicks, M. P., Blanton, M. G., Janak, P. H., & Olive, M. F. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0362-y · Cited by 207
Glucocorticoids, chronic stress, and obesity
Dallman, M. F., Pecoraro, N. C., La Fleur, S. E., Warne, J. P., Ginsberg, A. B., Akana, S. F., Laugero, K. C., Houshyar, H., Strack, A. M., Bhatnagar, S., et al. (2006) · Progress in Brain Research · doi:10.1016/s0079-6123(06)53004-3 · Cited by 198
Heilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
Regev, L., Neufeld-Cohen, A., Tsoory, M., Kuperman, Y., Getselter, D., Gil, S., & Chen, A. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.64 · Cited by 110
Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm
Farley, S., Apazoglou, K., Witkin, J. M., Giros, B., & Tzavara, E. T. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991076 · Cited by 96
Evidence for the role of corticotropin-releasing factor in major depressive disorder
Waters, R. P., Rivalan, M., Bangasser, D. A., Deussing, J. M., Ising, M., Wood, S. K., Holsboer, F., & Summers, C. H. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.011 · Cited by 93
Stress-Induced Potentiation of Cocaine Reward: A Role for CRFR1 and CREB
Kreibich, A. S., Briand, L., Cleck, J. N., Ecke, L., Rice, K. C., & Blendy, J. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.91 · Cited by 89
“…of CREB as a putative downstream signaling molecule for CRF. Finally, antalarmin has also been shown to have mixed effects on immobility in the FS test, with data demonstrating decreased immobility (Griebel et al, 2002; Land et al, 2008) as well as no change in behavior (Jutkiewicz et al, 2005).”
Claustre, Y., Leonetti, M., Santucci, V., Bougault, I., Desvignes, C., Rouquier, L., Aubin, N., Keane, P., Busch, S., Chen, Y., et al. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.011 · Cited by 59
Self-citationSotnikov, S. V., Markt, P. O., Malik, V, Chekmareva, N. Y., Naik, R. R., Sah, A., Singewald, N., Holsboer, F., Czibere, L., & Landgraf, R. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.127 · Cited by 49
Hascoët, M., & Bourin, M. (2009) · Neuromethods · doi:10.1007/978-1-60761-303-9_11 · Cited by 26
Metadata
- Authors
- Griebel, G., Simiand, J., Steinberg, R., Jung, M., Gully, D., Roger, P., Geslin, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 301
- Issue
- 1
- Pages
- 333-345
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2098391261
- Cited by
- 238
- References
- 2
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.